---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-24-000116"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:58:45.637453+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lilly Q1 revenue up 26% to $8.77B; raises full-year guidance by $2B

## Summary
- Q1 reported EPS $2.48 (up 66% YoY); non-GAAP EPS $2.58 (up 59% YoY), including $0.10 acquired IPR&D charges.
- Revenue $8.77B, driven by Mounjaro, Zepbound, Verzenio, Jardiance; raised FY2024 revenue guidance by $2.0B.
- Raises FY2024 reported EPS guidance to $13.05-$13.55 and non-GAAP EPS to $13.50-$14.00.
- Pipeline progress: positive Phase 3 tirzepatide for OSA, mirikizumab submission for Crohn's, lebrikizumab resubmission.
- Agreement to acquire injectable medicine manufacturing facility from Nexus Pharmaceuticals; broke ground on $2.5B German site.

## SEC filing metadata
- accession: 0000059478-24-000116
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947824000116/0000059478-24-000116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947824000116/lly-20240430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-24-000116
- JSON: https://secwatch.observer/filing/0000059478-24-000116.json
- Plain text: https://secwatch.observer/filing/0000059478-24-000116.txt

## Key facts
- Earnings Releases
  ELI LILLY & Co reported first quarter of 2024 results: revenue $8,768.0, net income $2,242.9, EPS $2.48. Guidance raised.
  - Period: first quarter of 2024
  - Revenue: $8,768.0
  - Net income: $2,242.9
  - EPS: $2.48
  - Guidance: raised
  - Result: reported results
  source text: on important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data First Quarter 2024 2023 % Change Revenue $ 8,768.0 $ 6,960.0 26% Net income – Reported 2,242.9 1,344.9 67% Earnings per share – Reported 2.48 1.49 66% Net income – Non-GAAP 2,335.3 1,463.9 60% Earnings per share – Non-GAAP 2.58
  evidence_url: https://www.sec.gov/Archives/edgar/data/59478/000005947824000116/0000059478-24-000116-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.